Nov-16 -

Melanoma Group

EORTC 18071 – Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma.

A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group.

EORTC found that resection of lymph nodes plus three years of additional treatment with ipilimumab, prolongs the time to disease reoccurrence or death in patients with stage III melanoma. A follow up in 2016 confirmed these results and showed that additional treatment with ipilimumab also improves overall survival.


Go to Top